This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel
Ichnos will receive an upfront payment of Euro 20.8 million as well as additional development and commercial milestone payments and tiered royalties based upon future global sales
It is a novel oral NLRP3 inflammasome inhibitor
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
A veteran in cell therapy and oncology commercialisation
All India Institute of Ayurveda hosts ministers and showcase their achievements
Subscribe To Our Newsletter & Stay Updated
